FDA
-
-
-
-
-
-
-
Organon Reports Results for the First Quarter Ended March 31, 2026
-
-
-
-
-
-
-
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years o
-
-
-
-
-
-
-
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
-
-
-
-
-
-
-
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
-
-
-
-
-
-
-
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
-
-
-
-
-
-
-
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
-
-
-
-
-
-
-
Organon (OGN) Completes Acquisition of Dermavant
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

